六、 ADC成功要素分析
凯泰资本生物技术团队认为成功的ADC公司有以下特点:1、独家技术:拥有独家技术,其可以是连接点技术(lysine、cysteine、cross-link、thiomab等)、连接物-毒素组合、新靶点(如DLL3)、非天然氨基酸剪辑技术等。最好在生产的均一性(DAR分布)与血清中稳定性中存在优势。2、优秀团队:拥有优秀的研发团队,核心人员包括化学、抗体发现、肿瘤生物学与CMC四方面。3、研发方向:研发方向方面,最好选择无有效药物的针对症的新靶点,或者热门单抗药的二线药物进行研究,并且靶点的生物学机制清晰。
参考资料:
· http://www.clinicaltrials.gov/
· http://www.chinadrugtrials.org.cn/
· http://www.scripps.edu/baran/images/grpmtgpdf/Sella_May_14.pdf/
· http://medhum.med.nyu.edu/view/10059/
· https://en.wikipedia.org/wiki/Gemtuzumab_ozogamicin/
· http://www.sohu.com/a/157632636_119995/
· https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4596905/
· http://www.abzena.com/development-services/bioconjugation/antibody-drug-conjugation/thiobridge-conjguation-technology/
· Seattle Genetics, ImmunoGen, Immunomedics, Abzena, Agensys, Celldex, Progenics, Genmab, Sorrento, Abbvie, Genentech, 丽珠单抗等公司官方网站
· EMA-Assessment Report for Herceptin
· EMA-Assessment Report for Kadcyla
· Nareshkumar Jain, Sean W. Smith, Sanjeevani Ghone and Bruce Tomczuk: Current ADC Linker Chemistry
· Nikolaos Diamantis and Udai Banerji: Antibody-drug conjugates—an emerging class of cancer treatment
· Beverly A. Teicher and Ravi V.J. Chari: Antibody conjugate therapeutics: challenges and potential
· Kyoji Tsuchikama and Zhiqiang An: Antibody-drug conjugates: recent advances in conjugation and linker chemistries
· 衣常红、高春芳: IgG糖基化修饰及其意义研究进展
· Alain Beck1, Liliane Goetsch1, Charles Dumontet2–4 and Nathalie Corvaïa:Strategies and challenges for the next generation of antibody–drug conjugates
· Polymetrics ppt
· 医药魔方-销售数据
· Seattle Genetics 2015; Takeda 2015; visiongain2015;Roche 2015,汤森路透报告